Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Program
-
Field
-
and experiments, such as Recombinant expression and purification of viral glycoproteins and other proteins in mammalian cells and E. coli (50%)with biochemical/biophysical characterization (using
-
the drivers and evolutionary factors influencing AMR in Brazil in pigs and examine a wider set of bacterial species, including Salmonella, E. coli and other bacterial pathogens identified through
-
University of California Agriculture and Natural Resources | Davis, California | United States | 21 days ago
chemical applications), driven by consumers and produce buyers, are often at odds with food safety risk reduction best practices. Food safety concerns include issues such as E. coli and other bacterial
-
in collaboration with Prof. Ingo Ebersberger (Goethe University Frankfurt). Genes of interest will be recombinantly expressed (e.g., in E. coli) or deleted in the respective patient isolates. Virulence
-
biology and microbiology is essential Experience with industrial biotechnology, synthetic biology or biochemistry is a plus Experience with the modification of E. coli, S. cerevisiae or Y lipolytica is a
-
constructs, which are then tested using the model organism E. coli. Candidates are also welcome to propose projects related to the work done in the lab. Members of our interdisciplinary team will leverage
-
complexes relevant to gene-regulation. Tasks: Cloning and production of recombinant proteins from E. coli and of RNA by means of in vitro transcription Qualitative/quantitative analyses of protein-RNA/DNA
-
relevant in gene-regulation. Tasks: Cloning and production of recombinant proteins from E. coli and of RNA by means of in vitro transcription Qualitative/quantitative analyses of protein-RNA/DNA complexes
-
. This position will focus on: (1) sustaining the long-term evolution experiment with E. coli; (2) employing and refining existing methods to measure phenotypic and genomic changes in this and other similar
-
activates its specific target in Pseudomonas aeruginosa, we will design, develop and test novel anti-biofilm compounds with broader activity against the WHO priority pathogens Escherichia coli, Klebsiella